Overview

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

ImClone LLC

Treatments:

Antibodies, Monoclonal
Docetaxel
Ramucirumab